Treatment of the hypogonadal infertile male - A review

Chee Kong Christopher Ho, Hui Meng Tan

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Testosterone treatment for hypogonadism is detrimental for men in reproductive age as it impairs spermatogenesis, and therefore affects fertility. It is, therefore, not indicated in men with hypogonadism and infertility. Aim: The aim of this review is to analyze current data regarding options of treatment for men with hypogonadism and infertility. Main Outcomes Measures: A comprehensive review of the current literature on management of infertility among hypogonadal men. Methods: A literature search using PubMed from 1980 to 2012 was done on articles published in the English language. The following medical subject heading terms were used: "infertility," "infertile," "hypogonadism;" "testosterone deficiency" and "men" or "male" and "treatment" or "management." Results: The options for hypogonadal testicular failure are limited. Hormonal treatment is by and large ineffective. For secondary hypogonadism (hypogonadotropic/normogonadotropic hypogonadism), the options include gonadotropin-releasing hormone, human chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG), follicle-stimulating hormone (FSH), and anti-estrogens and aromatase inhibitors. Dopamine antagonist is indicated for prolactinoma. Artificial reproductive technique is indicated for primary testicular failure and also when medical therapy fails. Conclusion: The most suitable option with the current data available is hCG with or without hMG/FSH. Testosterone supplementation should be avoided, but if they are already on it, it is still possible for a return of normal sperm production within 1 year after discontinuing testosterone. Ho CCK and Tan HM. Treatment of the hypogonadal infertile male-A review.

Original languageEnglish
Pages (from-to)42-49
Number of pages8
JournalSexual Medicine Reviews
Volume1
Issue number1
DOIs
Publication statusPublished - 2013

Fingerprint

Hypogonadism
Infertility
Testosterone
Menotropins
Follicle Stimulating Hormone
Chorionic Gonadotropin
Therapeutics
Medical Subject Headings
Reproductive Techniques
Prolactinoma
Aromatase Inhibitors
Dopamine Antagonists
Spermatogenesis
PubMed
Gonadotropin-Releasing Hormone
Fertility
Spermatozoa
Estrogens
Language
Outcome Assessment (Health Care)

Keywords

  • Hormonal
  • Hypogonadism
  • Infertility
  • Men
  • Treatment

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology
  • Obstetrics and Gynaecology
  • Dermatology

Cite this

Treatment of the hypogonadal infertile male - A review. / Ho, Chee Kong Christopher; Tan, Hui Meng.

In: Sexual Medicine Reviews, Vol. 1, No. 1, 2013, p. 42-49.

Research output: Contribution to journalReview article

Ho, Chee Kong Christopher ; Tan, Hui Meng. / Treatment of the hypogonadal infertile male - A review. In: Sexual Medicine Reviews. 2013 ; Vol. 1, No. 1. pp. 42-49.
@article{ae4cf62c80b647a7834f8ec47ba12d21,
title = "Treatment of the hypogonadal infertile male - A review",
abstract = "Introduction: Testosterone treatment for hypogonadism is detrimental for men in reproductive age as it impairs spermatogenesis, and therefore affects fertility. It is, therefore, not indicated in men with hypogonadism and infertility. Aim: The aim of this review is to analyze current data regarding options of treatment for men with hypogonadism and infertility. Main Outcomes Measures: A comprehensive review of the current literature on management of infertility among hypogonadal men. Methods: A literature search using PubMed from 1980 to 2012 was done on articles published in the English language. The following medical subject heading terms were used: {"}infertility,{"} {"}infertile,{"} {"}hypogonadism;{"} {"}testosterone deficiency{"} and {"}men{"} or {"}male{"} and {"}treatment{"} or {"}management.{"} Results: The options for hypogonadal testicular failure are limited. Hormonal treatment is by and large ineffective. For secondary hypogonadism (hypogonadotropic/normogonadotropic hypogonadism), the options include gonadotropin-releasing hormone, human chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG), follicle-stimulating hormone (FSH), and anti-estrogens and aromatase inhibitors. Dopamine antagonist is indicated for prolactinoma. Artificial reproductive technique is indicated for primary testicular failure and also when medical therapy fails. Conclusion: The most suitable option with the current data available is hCG with or without hMG/FSH. Testosterone supplementation should be avoided, but if they are already on it, it is still possible for a return of normal sperm production within 1 year after discontinuing testosterone. Ho CCK and Tan HM. Treatment of the hypogonadal infertile male-A review.",
keywords = "Hormonal, Hypogonadism, Infertility, Men, Treatment",
author = "Ho, {Chee Kong Christopher} and Tan, {Hui Meng}",
year = "2013",
doi = "10.1002/smrj.4",
language = "English",
volume = "1",
pages = "42--49",
journal = "Sexual Medicine Reviews",
issn = "2050-0513",
publisher = "John Wiley & Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment of the hypogonadal infertile male - A review

AU - Ho, Chee Kong Christopher

AU - Tan, Hui Meng

PY - 2013

Y1 - 2013

N2 - Introduction: Testosterone treatment for hypogonadism is detrimental for men in reproductive age as it impairs spermatogenesis, and therefore affects fertility. It is, therefore, not indicated in men with hypogonadism and infertility. Aim: The aim of this review is to analyze current data regarding options of treatment for men with hypogonadism and infertility. Main Outcomes Measures: A comprehensive review of the current literature on management of infertility among hypogonadal men. Methods: A literature search using PubMed from 1980 to 2012 was done on articles published in the English language. The following medical subject heading terms were used: "infertility," "infertile," "hypogonadism;" "testosterone deficiency" and "men" or "male" and "treatment" or "management." Results: The options for hypogonadal testicular failure are limited. Hormonal treatment is by and large ineffective. For secondary hypogonadism (hypogonadotropic/normogonadotropic hypogonadism), the options include gonadotropin-releasing hormone, human chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG), follicle-stimulating hormone (FSH), and anti-estrogens and aromatase inhibitors. Dopamine antagonist is indicated for prolactinoma. Artificial reproductive technique is indicated for primary testicular failure and also when medical therapy fails. Conclusion: The most suitable option with the current data available is hCG with or without hMG/FSH. Testosterone supplementation should be avoided, but if they are already on it, it is still possible for a return of normal sperm production within 1 year after discontinuing testosterone. Ho CCK and Tan HM. Treatment of the hypogonadal infertile male-A review.

AB - Introduction: Testosterone treatment for hypogonadism is detrimental for men in reproductive age as it impairs spermatogenesis, and therefore affects fertility. It is, therefore, not indicated in men with hypogonadism and infertility. Aim: The aim of this review is to analyze current data regarding options of treatment for men with hypogonadism and infertility. Main Outcomes Measures: A comprehensive review of the current literature on management of infertility among hypogonadal men. Methods: A literature search using PubMed from 1980 to 2012 was done on articles published in the English language. The following medical subject heading terms were used: "infertility," "infertile," "hypogonadism;" "testosterone deficiency" and "men" or "male" and "treatment" or "management." Results: The options for hypogonadal testicular failure are limited. Hormonal treatment is by and large ineffective. For secondary hypogonadism (hypogonadotropic/normogonadotropic hypogonadism), the options include gonadotropin-releasing hormone, human chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG), follicle-stimulating hormone (FSH), and anti-estrogens and aromatase inhibitors. Dopamine antagonist is indicated for prolactinoma. Artificial reproductive technique is indicated for primary testicular failure and also when medical therapy fails. Conclusion: The most suitable option with the current data available is hCG with or without hMG/FSH. Testosterone supplementation should be avoided, but if they are already on it, it is still possible for a return of normal sperm production within 1 year after discontinuing testosterone. Ho CCK and Tan HM. Treatment of the hypogonadal infertile male-A review.

KW - Hormonal

KW - Hypogonadism

KW - Infertility

KW - Men

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84979832134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979832134&partnerID=8YFLogxK

U2 - 10.1002/smrj.4

DO - 10.1002/smrj.4

M3 - Review article

AN - SCOPUS:84979832134

VL - 1

SP - 42

EP - 49

JO - Sexual Medicine Reviews

JF - Sexual Medicine Reviews

SN - 2050-0513

IS - 1

ER -